To quantify and characterize duplicated tests performed during the staging of localized colon cancer in the Medicare population.
in the United States. 1 Appropriate staging of these tumors is necessary for informed therapeutic decisions. Clinical staging is intended to detect metastatic disease that rules out the ability to perform curative intent surgical resection of tumor. Clinical guidelines for the diagnosis and staging of colon cancer recommend the use of colonoscopy, abdominal and pelvic computed tomography (CT) scans, [2] [3] [4] [5] [6] [7] and pathologic examination of the surgical specimen for localized tumors.
Health care costs in the United States are projected to account for 20% of the gross domestic product in 2020. 8 A key measure to cut down costs is the avoidance of services that do not benefit patients. 9, 10 The "Choosing Wisely" campaign explicitly points at the elimination of duplicated tests as a benefit of promoting conversations between physicians and patients. 11 Thus, avoidance of unnecessary tests for the diagnosis and staging of colon cancer might be a potential target for cost-containment measures.
Medicare patients receive coverage for all tests required for diagnosis and staging of colon cancer. While imposing no restrictions on the number of tests covered, Medicare encourages patients to avoid unnecessary duplication of tests. 12 The proportion of duplicated tests is, however, unknown. If diagnostic workup includes duplicative workup, there is a potential strategy for improving care quality while also controlling health care costs. Here we quantify and characterize the frequency of duplicated tests performed in the fee for service Medicare population during the clinical staging of early-stage colon cancer. 
METHODS

Study Population
The study cohort was identified from the SEER-Medicare database, which is a linkage of patient demographic and tumor-specific variables collected by 17 SEER cancer registries across 12 states with Medicare claim files from the Centers for Medicare and Medicaid Services. 13 SEER data are summarized in the Patient Entitlement and Diagnosis Summary File (PEDSF), which is linked with 100% of Medicare claims. For the current study we used Medicare claims from the Inpatient, Outpatient, Home Health Agency, Durable Medical Equipment (DME), Medpar, and National Claims History (NCH) files. Provider characteristics are extracted from the Hospital files, which contain information on hospital characteristics for years 1996, 1998, and 2000 to 2009.
Our analysis includes patients 66 years (to allow for at least 1 y of claims before diagnosis) or older, with a histologic diagnosis of invasive colon adenocarcinoma between 1996 (when hospital information first became available) and 2009 in a SEER area. We excluded rectal cancer and rectosigmoid tumors (which may require additional staging like magnetic resonance imaging or endoscopic ultrasound) and cancers for which the reporting source was nursing home/ hospice, autopsy, or death certificate. To ensure complete ascertainment of health services, patients had to be enrolled in parts A and B and not in an HMO during the 6 months before and after diagnosis. We excluded patients diagnosed in Louisiana in 2005 because of the disruption of data collection following hurricane Katrina.
We considered a patient as adequately staged and ready for a therapeutic decision after having received a colonoscopy, an abdominal CT scan, and a pelvic CT scan, as prescribed by the National Comprehensive Cancer Network and European Society for Medical Oncology. [2] [3] [4] [5] [6] [7] We did not require a chest CT scan, which is considered by some guidelines, 6 but not others 7, 14 (see Table, Supplemental Digital Content 1, http://links.lww.com/MLR/A803, for codes used to identify these tests). Tests are extracted from the claims 6 months before and after SEER date of diagnosis.
Definition of Duplicated Test
Any abdominal CT scan or pelvic CT scan received between the date when the patient was completely staged (see above) and the date of first treatment was considered a duplicate, with the exception of scans performed because of acute conditions 15 
Covariates
Demographic characteristics (age, sex, race, marital status, urbanicity), tumor features (TNM stage, grade of tumor differentiation, date of diagnosis), and census tract features (census region, percentage of black population, percentage of residents living below the poverty level, percentage of residents aged 25 or older with <12 y of education, percentage of residents speaking English not well/not at all at age 65+, median income) were extracted from the PEDSF file. Comorbidities were summarized using the Deyo-Charlson-Klabunde comorbidity index, 16 derived from the inpatient and outpatient Medicare claims for the period between 12 months and 1 month before diagnosis. To assess health services utilization, we computed a "preventive score," 17 the number of "low complexity visits" in the 24 months 1 year before diagnosis, and emergency room visits.
The provider performing the tests was linked with the institution information on the Hospital file. The Outsaf and Medpar files, but not the NCH file, contain a variable that allows linkage of providers with institutions without identifiers. NCH claims can correspond to either a test performed by a free-standing facility or to a professional service performed at an institutional provider (and thus also recorded in the Outsaf or Medpar files). We thus classified patients according to the type of institution involved in their staging workup: all tests performed in institutional nonprofit/government centers, at least 1 test in a proprietary center, and all tests in free-standing facilities or free-standing facilities plus nonprofit/government centers (see Table in Supplemental Digital Content 1, http://links.lww.com/MLR/A803, for the codes used to extract this information).
Mortality Analysis
For each patient, follow-up started at complete staging (see above) and ended at date of death or administrative cutoff date (in PEDSF file, December 31, 2010), whichever occurred earlier. We estimated the mortality hazard ratio (HR) for "receiving at least 1 duplicated test" versus "not receiving any duplicated test" within 3 months of complete staging. To do so, we fit a weighted pooled logistic model that included an indicator for duplicated tests, a flexible function of time (restricted cubic splines to estimate the baseline hazard), and the baseline covariates described above. We calculated robust standard errors to compute conservative 95% confidence intervals (CIs) for the effect estimate.
As in previous analyses of exposures that are not fully determined at baseline, we used data replication, censoring, and inverse probability weighting 18, 19 to adjust for the timevarying covariates: visits to the emergency room, clinical evaluations, change in comorbidity index, and development of large bowel obstruction. We then stabilized the weights to emulate a uniform duplicated test administration during 3 months. 20 Like previous applications of inverse probability weighting, [21] [22] [23] we truncated weights at percentile 99. All analyses were conducted with SAS, version 9.3 (SAS Institute, Cary, NC).
RESULTS
Of 75,840 eligible patients, 36,291 had complete staging: 25% stage I, 43% stage II, and 33% stage III (Fig. 1 ). We found that 2680 (7.4%) patients had at least 1 duplicated CT scan. Of the 2680 patients with duplicated tests, 68% received 1 duplicated abdominal CT scan plus 1 duplicated pelvic CT scan, and only 8% received >2 duplicated tests (see Table, Supplemental Digital Content 3, http://links.lww.com/MLR/A805). After complete staging, a colonoscopy was repeated in 5.5% of the patients. Table 1 shows the baseline characteristics of the patients. Patients receiving a duplicated CT scan had a higher comorbidity score; lived in census areas with a higher percentage of high-school dropouts, residents below poverty line, black race/ethnicity, and lower median incomes; and were more likely to have anemia, asthenia, and gastrointestinal symptoms in the 6 months before diagnosis.
Patients with duplicated CT scans had more clinical evaluations and were more likely to visit the emergency department in the timespan from being completely staged to first treatment (Table 2) . Patients with duplicated CT scans also had a longer median time from staging to first treatment (17 d, interquartile range from 7 to 35 vs. 9 d, interquartile range from 3 to 20). First treatment received was surgery in 89% and 96% of the patients with and without duplicates, respectively. The use of chemotherapy or radiotherapy as first treatment was marginal ( Table 2) .
Fifty percent of patients received complete staging in nonprofit/government centers, 8% received at least 1 staging test in a proprietary center, and 42% received staging tests in free-standing facilities with or without tests in institutional nonprofit/government centers. The percentage of patients receiving duplicates was 6%, 9%, and 8% in these 3 groups, respectively. The all-cause mortality HR for having received a duplicated CT scan was 1.22 (95% CI, 1.16-1.28). The corresponding HR for colon cancer-specific mortality was 1.23 (95% CI, 1.14-1.32) (see Table, Supplemental Digital Content 4, http://links.lww.com/MLR/A806, for more details on the survival analysis).
DISCUSSION
We found that 7% of abdominal or pelvic CT scans were duplicated in the staging of localized colon cancer in Medicare patients. Compared with patients without duplicated CT scans, those with duplicates had a higher comorbidity index, were more symptomatic, visited the emergency room more often, and received surgery as first treatment less often. These findings suggest that patients receiving duplicate tests were more frail and complex, which may warrant the additional testing.
The higher mortality among patients receiving duplicate CT scans also suggests that the duplicates may often be clinically indicated for reasons not captured in the Medicare data, such as performance status and abnormal test results. This explanation is further supported by the attenuation of the mortality HR after adjusting for baseline and time-varying confounders, together with the smaller attenuation observed for cancer-specific mortality (see Table, Supplemental Digital The short timespan from complete staging to the first treatment (median 9 d) indicates a timely administration of treatment to patients with localized colon cancer. Although patients receiving duplicates are treated a few days later on average, it is unlikely that this delay can explain the association between duplicated CT scans and mortality.
The cost of cancer care is estimated to grow from $125 billion in 2010 to $173 billion in 2020 in the United States. 24 Aging of the US population is argued as one of the drivers of this cost increase 25 and, in the case of colorectal cancer, the 12 months after diagnosis account for most of the expenses. 24 Our analysis targeted elderly population in the initial phase of colorectal cancer diagnosis, and provided reassurance of an adequate use of Medicare resources in this population.
Our analysis has the data limitations inherent to claimbased analyses and is restricted to patients over 66 years residing in SEER states. There is a possibility of occasional coding of rectal cancer as colon cancer, or vice versa. However, the small proportion of radiotherapy as first therapy suggests that this potential miscoding would have been infrequent. Some diagnostic tests may have been missed if some patients were using health care providers outside Medicare. However, when we restricted the analysis to the 27,158 individuals with an evaluation for a colon cancer-related symptom in the 6 months before diagnosis (ie, those more likely to have been diagnosed and staged within Medicare), results did not change materially.
In summary, we found a 7% frequency of duplicated CT scans for disease staging, which may be partly explained by the higher complexity of these patients, and timely delivery of treatment among elderly Medicare patients with localized colon cancer.
